The US Oncology Network and McKesson Specialty Health Affiliated Investigators Participate in Studies Featured at ASCO 2012

May 30, 2012

Company News Release

More than 90 leading investigators affiliated with US Oncology Research, The US Oncology Network and McKesson Specialty Health participated in over 60 studies that will be presented, displayed, or published at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) held June 1-5 at McCormick Place in Chicago. Of those studies, 12 will be presented as oral presentations including a plenary session regarding prostate cancer co-authored by US Oncology Research affiliated physician, Nicholas Vogelzang, MD.

“The plenary session will focus on results from an exciting international Phase III clinical trial,” said Nicholas Vogelzang, MD, oncologist at Comprehensive Cancer Centers of Nevada, co-chair of the Genitourinary Committee for US Oncology Research, and the communications chair of the 2012 ASCO Annual Meeting. “This study looked at how androgen deprivation, intermittent versus continuous, affected hormone sensitive metastatic prostate cancer patients.”

“Practices and investigators affiliated with US Oncology Research continue to lead the war on cancer through development, collaboration and participation in clinical trials evaluating the latest cutting edge therapies,” said Thomas Hutson, DO, PharmD, FACP, oncologist with Texas Oncology and co-chair of the Genitourinary Committee for US Oncology Research. “With more than 60 US Oncology Research affiliated studies being featured at ASCO, this marks one of the most successful years in clinical research for us. In fact, since the mid 1990s, US Oncology Research has enrolled more than 52,000 patients into clinical trials making huge strides in the treatment of cancer across several indications.”

A part of McKesson Specialty Health, US Oncology Research enables community-based oncologists, many of whom are affiliated with The US Oncology Network, to participate in clinical research studies. US Oncology Research has a long history of bringing innovative and successful agents to market. To date, US Oncology Research has played a role in the development of 43 FDA approved cancer fighting therapies.

Studies that affiliated investigators are part of include:

Oral Presentations:
1. Sunday, June 3, 3:15-3:30pm, N Hall B1 (Plenary Session)
Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial.
Maha Hussain, Catherine M. Tangen, Celestia S. Higano, E. David Crawford, Glenn Liu, George Wilding, Stephen Prescott, Atif Akdas, Eric Jay Small, Nancy Ann Dawson, Bryan J Donnelly, Peter Venner, Ulka N. Vaishampayan, Paul F. Schellhammer, David I. Quinn, Derek Raghavan, Nicholas J. Vogelzang, Ian Murchie Thompson

2. Monday, June 4, 8:00-11:00am, S100bc
Circulating tumor cell counts (CTC) as prognostic of overall survival (OS) in SWOG S0421-docetaxel with or without atrasentan for metastatic castration resistant prostate cancer (mCRPC).
Nicholas J. Vogelzang, Benjamin Ely, Louis M. Fink, Amir Goldkorn, Catherine M. Tangen, Przemyslaw Twardowski, Peter J. Van Veldhuizen, Neeraj Agarwal, Michael Anthony Carducci, J. P. Monk, Ram H Datar, Mark Garzotto, Philip C. Mack, Primo Lara, Celestia S. Higano, Maha Hussain, David I. Quinn, Richard J Cote, Ian Murchie Thompson

3. Saturday, June 2, 1:30-1:45pm, N Hall B1
A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer.
Ian E. Krop, Cristina Saura, Jordi Rodon Ahnert, Carlos Becerra, Carolyn D. Britten, Steven J. Isakoff, David Demanse, Wolfgang Hackl, Cornelia Quadt, Antonio P. Silva, Howard A. Burris, Maysa M. Abu-Khalaf, José Baselga

4. Saturday, June 2, 3:15-3:30pm, E Arie Crown Theater
Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial.
Robert John Motzer, Dmitry Nosov, Tim Eisen, Igor N. Bondarenko, Vladmir Lesovoy, Oleg N. Lipatov, Piotr Tomczak, Alexey A. Lyulko, Anna Alyasova, Mihai Harza, Mikhail Kogan, Boris Y. Alexeev, Cora N. Sternberg, Cezary Szczylik, Joshua Zhang, Andrew Louis Strahs, Brooke Esteves, William J. Slichenmyer, Anna Berkenblit, Thomas E. Hutson

5. Saturday, June 2, 5:15-5:30pm, E Hall D1
Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT).
Chris Verslype, Allen Lee Cohn, Robin Katie Kelley, Tsai-Shen Yang, Wu-Chou Su, David A. Ramies, Yihua Lee, Xiaodong Shen, Eric Van Cutsem

6. Monday, June 4, 8:45-9:00am, E Arie Crown Theater
Analysis of molecular mechanisms of response and resistance to vemurafenib (vem) in BRAF V600E melanoma.
Jeffrey Alan Sosman, Anna C. Pavlick, Lynn Mara Schuchter, Karl D Lewis, Grant A. McArthur, Charles Lance Cowey, Stergios J Moschos, Keith T. Flaherty, Kevin B. Kim, Jeffrey Weber, Peter Hersey, Georgina V. Long, Donald P. Lawrence, Mark Kockx, Olivia Spleiss, Astrid Koehler, Gideon Bollag, Andrew K. Joe, Kerstin Trunzer, Antoni Ribas

7. Tuesday, June 5, 11:00-11:15am, E Arie Crown Theater
Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II non-randomized expansion cohort (NRE).
Matthew Raymond Smith, Christopher Sweeney, Dana E. Rathkopf, Howard I. Scher, Christopher Logothetis, Daniel J. George, Celestia S. Higano, Evan Y. Yu, Andrea Lynne Harzstark, Eric Jay Small, A. Oliver Sartor, Michael S. Gordon, Nicholas J. Vogelzang, David C. Smith, Maha Hussain, Johann Sebastian De Bono, Naomi B. Haas, Christian Scheffold, Yihua Lee, Paul G. Corn

Sunday, June 3, 10:00-10:15am, E Hall D1
Results of the X-PECT study: A phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC).
Johanna C. Bendell, Thomas J. Ervin, Neil N. Senzer, Donald A. Richards, Irfan Firdaus, A. Craig Lockhart, Allen Lee Cohn, Mansoor N. Saleh, Lesa R. Gardner, Peter Sportelli, Cathy Eng

Monday, June 4, 10:15-10:30am, E354a
The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): Interim results of a phase Ib/II study.
John C. Byrd, Richard R. Furman, Steven E. Coutre, Jan Andreas Burger, Kristie A. Blum, Jeff Porter Sharman, Ian W. Flinn, Barbara W. Grant, Nyla A. Heerema, Amy J Johnson, Tasheda Navarro, Danelle Frances James, Eric Hedrick, Susan Mary O'Brien

Monday, June 4, 3:30-3:45pm, E Hall D2
SELECT: Randomized phase III study of docetaxel (D) or pemetrexed (P) with or without cetuximab (C) in recurrent or progressive non-small cell lung cancer (NSCLC) after platinum-based therapy.
Edward S. Kim, Marcus A. Neubauer, Allen Lee Cohn, Lee Steven Schwartzberg, Lawrence E. Garbo, John Robert Caton, Francisco Robert, Terry Katz, Sreenivas Chittoor, Lorinda Simms, Scott Saxman

Tuesday, June 5, 9:45am-12:45pm, E Arie Crown Theater
Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).
Chris Parker, Sten Nilsson, Daniel Heinrich, Joe M. O'Sullivan, Sophie D. Fossa, Ales Chodacki, Pawel J. Wiechno, John P. Logue, Mihalj Seke, Anders Widmark, Dag Clement Johannessen, Peter Hoskin, David Bottomley, Robert Edward Coleman, Nicholas J. Vogelzang, C. Gillies O'Bryan-Tear, Jose E. Garcia-Vargas, Minghua Shan, A. Oliver Sartor

12. Tuesday, June 5, 9:45am-12:45pm, E Arie Crown Theater
SWOG S0421: Phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC).
David I. Quinn, Catherine M. Tangen, Maha Hussain, Primo Lara, Amir Goldkorn, Mark Garzotto, Philip C. Mack, Michael Anthony Carducci, J. P. Monk, Przemyslaw Twardowski, Peter J. Van Veldhuizen, Neeraj Agarwal, Celestia S. Higano, Nicholas J. Vogelzang, Ian Murchie Thompson

Posters:
1. Sunday, June 3, 8:00am-12:00pm, S Hall A2, Poster Board #5B
Phase I results of a phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC) patients previously treated with VEGFR tyrosine kinase inhibitors.
Thomas E. Hutson, Long H. Dang, Richard C. Lauer, Alexander Starodub, Ralph J. Hauke, Matt D. Galsky, Kathryn A. Bylow, Theodore Logan, Charles Lance Cowey, David C. Bibby, Gabriel Kremmidiotis, Elizabeth E. Doolin, Tina C. Lavranos, Guru Sonpavde, Noah M. Hahn, Christopher Sweeney, John Sarantopoulos

2. Saturday, June 2, 8:00am-12:00pm, S Hall A2, Poster Board #9G
Lapatinib in HER2+ early breast cancer: Quality of life analysis.
Frances Boyle, Ian Edward Smith, Joyce O'Shaughnessy, Bent Ejlertsen, Manfred Kaufmann, Aman Buzdar, Pierre Fumoleau, William John Gradishar, Miguel Martin, Beverly Moy, Martine J. Piccart-Gebhart, Kathleen I. Pritchard, Deborah Lindquist, Mayur Amonkar, Yingjie Huang, Lisa Simone Williams, Qing Wang, Dianne M Finkelstein, Paul Edward Goss

3. Monday, June 4, 8:00am-12:00pm, S Hall A2, Poster Board #37G
Effect of the 12-gene colon cancer assay results on treatment recommendations in patients with stage II colon cancer.
Thomas H. Cartwright, Calvin Chao, Margarita Lopatin, Tanya G. Bentley, Michael S. Broder, Eunice Chang

4. Sunday, June 3, 8:00am-12:00pm, S Hall A2, Poster Board #14E
Neoadjuvant therapy preceding cytoreductive nephrectomy to develop individualized first-line therapy with everolimus for advanced renal cell carcinoma (RCC).
Guru Sonpavde, Gilad Amiel, Vitaly Margulis, Richard E Link, Seth P. Lerner, Ganesh Raj, Wesley A Mayer, Ganesh S. Palapattu, Yair Lotan, Arthur I. Sagalowsky, Linda C Higgins, Sebrina A Tello, Andrea Pavia-Jimenez, Dendra VonMerveldt, James Brugarolas

5. Saturday, June 2, 8:00am-12:00pm, S Hall A2, Poster Board #2E
Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses.
Joyce O'Shaughnessy, John E. Pippen, Devchand Paul, Christopher T. Stokoe, Joanne Lorraine Blum, Lea Krekow, Frankie Ann Holmes, Christine Lopez-Diaz, Svetislava J. Vukelja, Deborah Lindquist, Scot M. Sedlacek, Ragene Ruth Rivera, Robert J. Brooks, Kristi McIntyre, Yunfei Wang

Monday, June 4, 1:15-5:15pm, S Hall A2, Poster Board #27C
Preliminary safety and efficacy of ruxolitinib in patients (pts) with primary and secondary myelofibrosis (MF) with platelet counts (PC) of 50–100x109/L.
Moshe Talpaz, Solomon I. Hamburg, Katarzyna Jamieson, Howard R. Terebelo, Lawrence Afrin, Elliott F. Winton, Michael A. Scola, Roger M. Lyons, Jimmie Huling Harvey, Chris E. Holmes, Gregory L. Ortega, Josef T. Prchal, Richard T. Silver, Maria R. Baer, Susan Kay Erickson-Viitanen, Peter O'Neill, Wei Peng, Lance Leopold, Hagop Kantarjian, Srdan Verstovsek

Monday, June 4, 1:15-5:15pm, S Hall A2, Poster Board #25C
Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy.
Srdan Verstovsek, Ruben A. Mesa, Jason R. Gotlib, Vikas Gupta, John F. DiPersio, John V. Catalano, Michael W.N. Deininger, Carole Brennan Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie Huling Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, William Sun, Hagop Kantarjian

Monday, June 4, 1:15-5:15pm, S Hall A2, Poster Board #10B
Changes in adjuvant breast cancer chemotherapy regimen selection over time in the community.
Debra A. Patt, Janet L. Espirito, Brian Turnwald, J. Russell Hoverman, Marcus A. Neubauer, Thomas H. Cartwright, Leslie T. Busby, Barry Don Brooks, Mark A. Sitarik, Michael A. Kolodziej, Roy A. Beveridge

Sunday, June 3, 8:00am-12:00pm, S Hall A2, Poster Board #35A
A single-arm, open-label, U.S. expanded access study of vemurafenib in patients with metastatic melanoma.
Lynn Mara Schuchter, Lawrence E. Flaherty, Omid Hamid, Gerald P. Linette, Sigrun Hallmeyer, Rene Gonzalez, Charles Lance Cowey, Anna C. Pavlick, Fred J. Kudrik, David H. Lawson, Kim Allyson Margolin, Antoni Ribas, David F. McDermott, James L. Khatcheressian, Keith T. Flaherty, Bann-Mo Day, Rolf Gerhard Linke, John D. Hainsworth

Monday, June 4, 8:00am-12:00pm, S Hall A2, Poster Board #16C
CD30 expression in nonlymphomatous malignancies.
Jeff Porter Sharman, Jerome H. Goldschmidt, John M. Burke, Beth A. Hellerstedt, Kristi McIntyre, Christopher A. Yasenchak, Thomas E. Boyd, Robert L. Ruxer, Dipti Patel-Donnelly, Fadi S. Braiteh, Andres Forero-Torres, Michael A. Savin, Tina Marie Albertson

Monday, June 4, 1:15-5:15pm, S Hall A2, Poster Board #11G
Variation in health-related quality of life (HRQOL) by ECOG performance status (PS) and fatigue among patients with chronic lymphocytic leukemia (CLL).
Christopher Flowers, Chris L Pashos, Mark Adam Weiss, Nicole Lamanna, Charles Michael Farber, Thomas J. Kipps, Susan Lerner, Neil E Kay, Jeff Porter Sharman, David L. Grinblatt, Ian W. Flinn, Mark Kozloff, Arlene S Swern, Zeba M. Khan, Thomas Street, Kristen Sullivan, Michael J. Keating, Ren Yu

Monday, June 4, 8:00am-12:00pm, S Hall A2, Poster Board #10C
Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial.
Guru Sonpavde, Gregory Russell Pond, Stephen John Clarke, Janette L. Vardy, S. L. Wang, Jolanda Paolini, Mariajose Lechuga, M. Dror Michaelson, Matthew Raymond Smith, Isan Chen, Edna Chow Maneval

Sunday, June 3, 8:00am-12:00pm, S Hall A2, Poster Board #10B
Phase I trial of NY-ESO-1/LAGE1 peptide vaccine for metastatic castration resistant prostate cancer (mCRPC).
Teresa Gray Hayes, Guru Sonpavde, Mingjun Wang, Yicheng Wang, Teresa Joe, Martha P. Mims, Michael M. Ittmann, Thomas M. Wheeler, Adrian P. Gee, Rongfu F Wang

14. Sunday, June 3, 8:00am-12:00pm, S Hall A2, Poster Board #3A
A phase II trial of neoadjuvant dasatinib (Neo-D) in muscle-invasive urothelial carcinoma of the bladder (miUCB): Hoosier Oncology Group GU07-122 trial.
Noah M. Hahn, Siamak Daneshmand, Edwin M. Posadas, Michael O. Koch, Richard Bihrle, Richard Foster, Timothy A. Masterson, Liang Cheng, Ziyue Liu, Timothy Breen, Mark T. Fleming, Ray Lance, Christopher W. Ryan, Christopher L. Corless, Matt D. Galsky, Ajjai Shivaram Alva, Carmen Mitchell, Steven S. Shen, Seth P. Lerner, Guru Sonpavde

15. Sunday, June 3, 8:00am-12:00pm, S Hall A2, Poster Board #12E
Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane.
Anthony E. Mega, Daniel Peter Petrylak, Philip Kantoff, Joe Stephenson, Nicholas J. Vogelzang, Robert Dreicer, Neal D. Shore, Nancy Stambler, Jennifer Carpenito, Paul D'Ambrosio, Robert Joseph Israel

16. Monday, June 4, 1:15-5:15pm, S Hall A2, Poster Board #34E
MLN9708, an investigational proteasome inhibitor, in patients (pts) with relapsed/refractory lymphoma: Emerging data from a phase I dose-escalation study.
Peter Martin, Julie E. Chang, Robert M. Rifkin, Ai-Min Hui, Deborah Berg, Neeraj Gupta, Guohui Liu, Alessandra Di Bacco, Sarit E. Assouline

17. Monday, June 4, 1:15-5:15pm, S Hall A2, Poster Board #51G
Isolation and expansion of circulating tumor cells (CTC) from melanoma patients using a novel cell culture technique.
John R. McGregor, Wolfram E. Samlowski, Shweta Tharkar, Sreekanth Donepudi, Soldano Ferrone

18. Sunday, June 3, 8:00am-12:00pm, S Hall A2, Poster Board #12H
Phase I clinical trial of galeterone (TOK-001), a multifunctional antiandrogen and CYP17 inhibitor in castration resistant prostate cancer (CRPC).
Robert B. Montgomery, Mario A. Eisenberger, Matthew Rettig, Franklin Chu, Roberto Pili, Joe Stephenson, Nicholas J. Vogelzang, Jodie Morrison, Mary-Ellen Taplin

19. Sunday, June 3, 8:00am-12:00pm, S Hall A2, Poster Board #12F
Results of telomerase activity measurements from live circulating tumor cells captured on a slot microfilter in a phase III SWOG-coordinated prostate cancer trial (S0421).
Amir Goldkorn, Benjamin Ely, David I. Quinn, Catherine M. Tangen, Yu-Chong Tai, Przemyslaw Twardowski, Peter J. Van Veldhuizen, Neeraj Agarwal, Michael Anthony Carducci, J. P. Monk, Mark Garzotto, Philip C. Mack, Primo Lara, Celestia S. Higano, Maha Hussain, Nicholas J. Vogelzang, Richard J Cote, Ian Murchie Thompson

20. Sunday, June 3, 8:00am-12:00pm, S Hall A2, Poster Board #46F
Analysis of a neoadjvant regimen with a fixed dose of doxorubicin followed by a 10-day course of 27 Gy radiation in the treatment of soft tissue sarcoma (STS) of the extremity/trunk.
John Mathews, Gerhard Maale, Donald E. Schwarz, James Fredric Strauss, Mark Feldman, Juan G. Posada, Ashwini Bhat

21. Saturday, June 2, 8:00am-12:00pm, S Hall A2, Poster Board: #47G
Safety and efficacy of eltrombopag (epag) versus placebo (pbo) for the treatment (tx) of chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors receiving gemcitabine (gem)-based chemotherapy (ctx): A phase I study.
Eric S. Winer, Howard Safran, Boguslawa Karaszewska, Donald A. Richards, Lee Hartner, Frederic Forget, Rodryg Ramlau, Kirushna Kumar, Bhabita Mayer, Brendan Mark Johnson, Conrad A. Messam, Yasser Mostafa Mostafa Kamel

Poster Discussions:
Monday, June 4, 1:15-5:15pm, E450a, Poster Board #2E
Discussion: 4:45-5:45pm, E Hall D1
Actionable targets in pancreatic cancer detected by immunohistochemistry (IHC), microarray (MA) fluorescent in situ hybridization (FISH), and mutational analysis.
Daniel D. Von Hoff, Ramesh K. Ramanathan, Douglas B. Evans, Michael J. Demeure, Todd Maney, Brian Wright, Zoran Gatalica, Matthew Jerome McGinniss

2. Saturday, June 2, 8:00am-12:00pm, S405, Poster Board #4
Discussion: 12:00-1:00pm, S406
Safety of the antimyostatin monoclonal antibody LY2495655 in healthy subjects and patients with advanced cancer.
Gayle S. Jameson, Daniel D. Von Hoff, Glen J. Weiss, Donald A. Richards, David A. Smith, Carlos Becerra, Mitchell C. Benson, Zheng Yuan, Deborah A Robins, Michael Turik, Margaret Wagner, Leijun Hu, Boris K. Lin

3. Saturday, June 2, 1:15-5:15pm, S405, Poster Board #15
Discussion: 4:45-5:45pm, S406
A five-arm, open-label, phase I/lb study to assess safety and tolerability of the oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with chemotherapy or erlotinib in patients with advanced solid tumors.
Carlos Becerra, Jeffrey R. Infante, Lawrence E. Garbo, Michael S. Gordon, David A. Smith, Fadi S. Braiteh, David R. Gandara, Robert M. Jotte, Karen L. Reckamp, Filip Janku, Howard A. Burris, Kevin M. Bellew, Olivia S. Gardner, Li Liu, Donna S Cox, Vijay Gopal Reddy Peddareddigari, George R. Blumenschein

4. Friday, June 1, 1:00-5:00pm, E450b, Poster Board #14
Discussion: 4:30-5:30pm, E Arie Crown Theater
Impact of age and medical comorbidity (MC) on adjuvant treatment outcomes for stage III colon cancer (CC): A pooled analysis of individual patient data from four randomized controlled trials.
Daniel G. Haller, Michael O'Connell, Thomas H. Cartwright, Christopher Twelves, Edward McKenna, Weijing Sun, Wasif M. Saif, Luen F. Lee, Greg Yothers, Hans-Joachim Schmoll

5. Sunday, June 3, 1:00-5:00pm, S450b, Poster Board #15
Discussion: 4:00-5:00pm, E Arie Crown Theater
Effect of oxaliplatin-based adjuvant therapy on post-relapse survival (PRS) in patients with stage III colon cancer: A pooled analysis of individual patient data from four randomized controlled trials.
Christopher Twelves, Hans-Joachim Schmoll, Michael O'Connell, Thomas H. Cartwright, Edward McKenna, Weijing Sun, Wasif M. Saif, Luen F. Lee, Greg Yothers, Daniel G. Haller

6. Sunday, June 3, 1:00-5:00pm, S450b, Poster Board #17
Discussion: 4:00-5:00pm, E Arie Crown Theater
Comparative evaluation of capecitabine or infusional leucovorin/5-fluorouracil (LV/5-FU) with or without oxaliplatin (Ox) for stage III colon cancer (CC): A pooled analysis of individual patient data from four randomized controlled trials.
Weijing Sun, Hans-Joachim Schmoll, Michael O'Connell, Thomas H. Cartwright, Christopher Twelves, Edward McKenna, Wasif M. Saif, Luen F. Lee, Greg Yothers, Daniel G. Haller

7. Monday, June 4, 1:15-5:15pm, E450b, Poster Board #9
Discussion: 4:45-5:45pm, N Hall B1
Final analysis of phase II study of ΕΖΝ 2208 (PEG-SN38) in metastatic breast cancer (MBC).
Cynthia R. C. Osborne, Joyce O'Shaughnessy, Frankie Ann Holmes, Hyun Sue Kim, Darren M. Kocs, Michael S. Steinberg, Paul D. Richards, Svetislava J. Vukelja, Noah C. Berkowitz, Aby Buchbinder

Monday, June 4, 1:15-5:15pm, E450b, Poster Board #8
Discussion: 4:45-5:45pm, N Hall B1
Tesetaxel: Activity of an oral taxane as first-line treatment in metastatic breast cancer.
Andrew David Seidman, Lee Steven Schwartzberg, Joyce O'Shaughnessy, Gabriella D'Andrea, Peter Rubin, Seth Katz, Hassan Danesi, Loretta Itri, Clifford Hudis

9. Saturday, June 2, 1:15-5:15pm, E450b, Poster Board #16
Discussion: 4:45-5:45pm, E353
CNS metastases as a site of progression on SWOG intergroup study S0008: A phase III trila of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 (BCT) versus high-dose interferon (HDI) in patients with high-risk melanoma.
Wolfram E. Samlowski, James Moon, Merle Witter, Michael B. Atkins, John M. Kirkwood, Megan Othus, Antoni Ribas, Vernon K. Sondak, Lawrence E. Flaherty

10. Saturday, June 2, 8:00am-12:00pm, E450a, Poster Board #1
Discussion: 12:00-1:00pm, E Arie Crown Theater
Time from prior chemotherapy (TFPC) as a prognostic factor in advanced urothelial carcinoma (UC) receiving second-line systemic therapy.
Gregory Russell Pond, Guru Sonpavde, Toni K. Choueiri, Angela Q. Qu, David J. Vaughn, Ronan Fougeray, Guenter Niegisch, Peter Albers, Yu-Ning Wong, Yoo-Joung Ko, Srikala S. Sridhar, Matt D. Galsky, Daniel Peter Petrylak, Tomasz M. Beer, Walter Michael Stadler, Peter H. O'Donnell, Cora N. Sternberg, Jonathan E. Rosenberg, Joaquim Bellmunt Molins

11. Saturday, June 2, 8:00am -12:00pm, E450a, Poster Board #5
Discussion: 12:00-1:00pm, E Arie Crown Theater
Prognostic model for overall survival in patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.
Matt D. Galsky, Susanne Krege, Chia-Chi Lin, Noah M. Hahn, Thorsten Ecke, Erin L. Moshier, Guru Sonpavde, James H. Godbold, William K. Oh, Aristotelis Bamias

12. Saturday, June 2, 8:00am-12:00pm, E450a, Poster Board #4
Discussion: 12:00-1:00pm, E Arie Crown Theater
Correlation of progression-free survival at 6 months (PFS6) with overall survival at 12 months (OS12) in an analysis of 10 trials of second-line therapy for advanced urothelial carcinoma (UC).
Benjamin Maughan, Kenneth M. Boucher, Neeraj Agarwal, Toni K. Choueiri, Angela Q. Qu, Nicholas J. Vogelzang, Ronan Fougeray, Guenter Niegisch, Peter Albers, Yu-Ning Wong, Yoo-Joung Ko, Srikala S. Sridhar, Matt D. Galsky, Daniel Peter Petrylak, Ulka N. Vaishampayan, Tomasz M. Beer, Cora N. Sternberg, Jonathan E. Rosenberg, Joaquim Bellmunt Molins, Guru Sonpavde

13. Saturday, June 2, 8:00am-12:00pm, E450b, Poster Board #17
Discussion: 12:00-1:00pm, E354a
Connect MM: The multiple myeloma (MM) disease registry – Incidence of second primary malignancies (SPM).
Robert M. Rifkin, Rafat Abonour, Rafael Fonseca, Cristina Gasparetto, Jayesh Mehta, Mohit Narang, Chris L Pashos, Sachdev P Thomas, Jatin J. Shah, Howard R. Terebelo, Kathleen Toomey, Neil Minton, Shankar Srinivasan, Thomas Street, Kristen Sullivan, Brian G. Durie

14. Saturday, June 2, 8:00am-12:00pm, E450b, Poster Board #12
Discussion: 12:00-1:00pm, E354a
Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL).
Jennifer R. Brown, Jeff Porter Sharman, Wael A. Harb, Kevin R. Kelly, Marshall T. Schreeder, John W. Sweetenham, Paul M. Barr, James M. Foran, Janice Lynn Gabrilove, Thomas J. Kipps, Shuo Ma, Susan Mary O'Brien, Erica Evans, Heather Lounsbury, Bruce A. Silver, Juswinder Singh, Kathryn Stiede, William Westlin, Steven Witowski, Daruka Mahadevan

15. Friday, June 1, 1:00-5:00pm, E450b, Poster Board #10
Discussion: 4:30-5:30pm, S406
A phase I/II study of the selective phosphatidylinositol 3-kinase-delta (PI3Kδ) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL).
Richard R. Furman, Jacqueline Claudia Barrientos, Jeff Porter Sharman, Sven De Vos, John Leonard, Steven E. Coutre, Marshall T. Schreeder, Nina D. Wagner-Johnston, Thomas E. Boyd, Nathan Hale Fowler, Ian W. Flinn, Ralph V. Boccia, Leanne Holes, Brian Joseph Lannutti, Dave Johnson, Thomas Michael Jahn, Langdon L. Miller

Tuesday, June 5, 8:00am-12:00pm, E450a, Poster Board #4
Discussion: 11:30am-12:30pm, E354a
Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT).
Beth A. Hellerstedt, Gerald Edelman, Nicholas J. Vogelzang, Harriet M. Kluger, Christopher A. Yasenchak, Xiaodong Shen, David A. Ramies, Michael S. Gordon, Primo Lara

Monday, June 4, 8:00am-12:00pm, E450a, Poster Board #12
Discussion: 11:30am-12:30pm, E Arie Crown Theater
Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC).
Oscar B. Goodman, Kim N. Chi, Arturo Molina, Christopher Logothetis, Robert J. Jones, John Staffurth, Scott A. North, Nicholas J. Vogelzang, Fred Saad, Paul N. Mainwaring, Stephen John Harland, Jinhui Li, Thian San Kheoh, Christopher M. Haqq, Howard I. Scher, Karim Fizazi

Monday, June 4, 8:00am-12:00pm, E450a, Poster Board #5
Discussion: 11:30am-12:30pm, E Arie Crown Theater
Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Interim results of a phase III trial (ALSYMPCA).
A. Oliver Sartor, Daniel Heinrich, Joe M. O'Sullivan, Sophie D. Fossa, Ales Chodacki, Pawel J. Wiechno, John P. Logue, Mihalj Seke, Anders Widmark, Dag Clement Johannessen, Sten Nilsson, Peter Hoskin, David Bottomley, Robert Edward Coleman, Nicholas J. Vogelzang, C. Gillies O'Bryan-Tear, Jose E. Garcia-Vargas, Minghua Shan, Chris Parker

19. Monday, June 4, 8:00am-12:00pm, E450a, Poster Board #1
Discussion: 11:30am-12:30pm, E Arie Crown Theater
SWOG 0421: Prognostic and predictive value of bone metabolism biomarkers (BMB) in castration resistant prostate cancer (CRPC) patients (pts) with skeletal metastases treated with docetaxel (DOC) with or without atrasentan (ATR).
Primo Lara, Benjamin Ely, David I. Quinn, Catherine M. Tangen, Erik Gertz, Philip C. Mack, Przemyslaw Twardowski, Nicholas J. Vogelzang, Maha Hussain, Ian Murchie Thompson, Marta Van Loan

20. Monday, June 4, 1:15-5:15pm, E450b, Poster Board: #10
Discussion: 4:45-5:45pm, N Hall B1
Everolimus with paclitaxel plus bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC): A randomized, double-blind, placebo-controlled phase II trial of the Sarah Cannon Research Institute (SCRI).
Denise Aysel Yardley, Linda D. Bosserman, Nancy Walker Peacock, Anne Favret, Susan Kay Morgan, Victor M. Priego, J. David Bass, Paula L. Griner, Howard A. Burris, John D. Hainsworth, Joyce O'Shaughnessy

Publish Only:
1. Guideline-based treatment utilization, treatment time and cost of chemotherapy for metastatic colon cancer patients treated in U.S. community oncology practices from 2005 to 2009.
Yen Phung, Zhaohui Wang, Inga Aksamit, Sarah G. Green, Karen Todoroff, Kimberly A. Bergstrom

2. Phase II trial of tamoxifen for progressive advanced urothelial carcinoma following prior chemotherapy.
Seth P. Lerner, Cora N. Sternberg, Mamoun Younes, Fabio Calabro, Linda Cerbone, A Chandrashekar, Carmen Mitchell, Steven S. Shen, Guru Sonpavde

3 Retrospective data study evaluating resource utilization among metastatic renal cell carcinoma patients receiving oral versus intravenous mTOR inhibitors.
Menaka Bhor, Thomas E. Hutson, Rahul Dhanda, Zhimei Liu, Nicholas J. Vogelzang

4. Treatment practice patterns and survival among patients with metastatic soft tissue sarcoma (mSTS) in a community setting in the United States.
Clara Chen, Rohit Borker, Rahul Dhanda, Eric Nadler

5. Sunitinib dosing, toxicity, and outcomes in first-line advanced renal cell carcinoma (aRCC): A US Oncology Network (USON) retrospective study.
Ian D. Schnadig, Thomas E. Hutson, Hsingwen Chung, Rahul Dhanda, Melissa Halm, Michael T. Forsyth, Nicholas J. Vogelzang

6. Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine.
Aimee Ginsburg Arlen, Thomas H. Cartwright, Lalan S. Wilfong, J. Russell Hoverman, Greg C Nelson, Brian Turnwald, Roy A. Beveridge

7. Efficacy and safety of IMO-2055, a novel TLR9 agonist, in combination with erlotinib (E) and bevacizumab (bev) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed following prior chemotherapy.
David A. Smith, Paul Conkling, Donald A. Richards, Maria Regina C. Flores, John J. Nemunaitis, Thomas E. Boyd, Alain C. Mita, Guillaume de La Bourdonnaye, David Wages, Alice Susannah Bexon

8. Race- and health-related quality of life among patients newly diagnosed with multiple myeloma.
Chris L Pashos, Brian G. Durie, Robert M. Rifkin, Rafat Abonour, Rafael Fonseca, Cristina Gasparetto, Jayesh Mehta, Mohit Narang, Jatin J. Shah, Howard R. Terebelo, Sachdev P. Thomas, Kathleen Toomey, Arlene S Swern, Gale Harding, Kristen Sullivan, Thomas Street, Zeba M. Khan

9. External validation of a sunitinib prognostic nomogram in patients (pts) with metastatic renal cell carcinoma (mRCC).
Changhong Yu, Michael W. Kattan, Thomas E. Hutson, Gary R. Hudes, Jinyu Yuan, Olga Valota, Robert John Motzer

10. A randomized, placebo-controlled, double blind, multicenter phase II adjuvant trial of the efficacy, immunogenicity, and safety of GI-4000 plus gem vs. gem alone in patients with resected pancreas cancer with activating RAS mutations/survival and immunology analysis of the R1 subgroup.
Peter Muscarella, Lalan S. Wilfong, Sharona B. Ross, Donald A. Richards, Julian Raynov, William E. Fisher, Patrick J. Flynn, Samuel H. Whiting, Alexander Rosemurgy, Frank E Harrell, Nathaniel D. Mercaldo, Scott Kosten, John Quiring, Sue Speyer, Joni Richman, John Ferraro, Claire Coeshott, Allen Cohn, Timothy C. Rodell, David Apelian

11. Pharmacokinetics (PK) of bendamustine when administered in combination with rituximab in patients with non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL).
Mary Bond, John M. Burke, Edward Hellriegel, Philmore Robertson, Luann Phillips, Elizabeth Ludwig, Mona Darwish

12. A phase I/II trial of melphalan (MEL) combined with panobinostat (PAN) for patients with relapsed or refractory (R/R) multiple myeloma (MM).
Ori Yellin, James R. Berenson, Ralph V. Boccia, Allen Lee Cohn, Paul Berard, Hassan Ghazal, Saad Jamshed, Edwin Kingsley, Wael A. Harb, Stephen J. Noga, Youram Nassir, Regina A. Swift, Robert A. Vescio

13. Oral low-dose cyclophosphamide, as a second-line agent, in patients with primary docetaxel refractory metastatic castration-resistant prostate cancer (mCRPC).
Daniela Shapiro, James Thomas Symanowski, Nicholas J. Vogelzang, Oscar B. Goodman